Finally, we found that Brusatol, an active ingredient in Brucea javanica, targeted FTL and NRF2, which might be a brand-new therapeutic strategy for patients with advanced ESCC. This evidence concerns the gene NFE2L2 and esophageal squamous cell carcinoma.